Tạp chí Tim mạch học Việt Nam

Article detail

Article detail description

Home
NGHIÊN CỨU LÂM SÀNG Issue: Số 94+95 , 2021 BỆNH SUY TIM

No translate

Vương Thị Ánh Tuyết: Bác sĩ nội trú, Đại học Y Hà Nội; Đỗ Kim Bảng: Viện Tim mạch Việt Nam - Bệnh viện Bạch Mai;
Published: August 20, 2026
Views: 323
DOI 10.58354/jvc.94.95.2021.162

Abstract

No translate

Keywords
No translate

References

1.
1. BenjaminEJ,MuntnerP,AlonsoA,etal. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139(10):e56-e528.
2.
2. Heidenreich PA, Albert NM, Allen LA, et al. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013;6(3):606-619.
3.
3. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation. 2007;116(13):1482-1487.
DOI: doi.org/10.1161/hhf.0b013e318291329a
4.
4. Adams KF, Jr., Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149(2):209-216.
5.
5. ClelandJG,SwedbergK,FollathF,etal. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003;24(5):442-463.
DOI: doi.org/10.1161/circulationaha.107.759662
6.
6. Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011;37(4):619-626.
7.
7. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch Intern Med. 2007;167(14):1493-1502.
DOI: doi.org/10.1016/j.ahj.2004.08.005
8.
8. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24(5):464-474.
9.
9. Nieminen MS, Brutsaert D, Dickstein K, et al. EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27(22):2725-2736.
DOI: doi.org/10.1016/s0195-668x(02)00823-0
10.
10. Ilieșiu AM, Hodorogea AS. Treatment of heart failure with preserved ejection fraction. In: Heart Failure: From Research to Clinical Practice. Springer; 2018:67-87.
11.
11. Alimonda AL, Nunez J, Nunez E, et al. Hyperuricemia in acute heart failure. More than a simple spectator? Eur J Intern Med. 2009;20(1):74-79.
DOI: doi.org/10.1007/s00134-010-2113-0
12.
12. Okazaki H, Shirakabe A, Kobayashi N, et al. The prognostic impact of uric acid in patients with severely decompensated acute heart failure. J Cardiol. 2016;68(5):384-391.
13.
13. PonikowskiP,VoorsA,AnkerS,etal. Authors/Task Force Members; Document Reviewers (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. 2016;18(8):891-975.
DOI: doi.org/10.1001/archinte.167.14.1493
14.
14. Sato N, Kajimoto K, Asai K, et al. Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. 2010;159(6):949-955. e941.
15.
15. Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A, journal J-CIJC. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. 2006;70(12):1617-1623.
DOI: doi.org/10.1016/s1062-1458(03)00299-x
16.
16. Shiba N, Shimokawa HJVH, Management R. Chronic heart failure in Japan: implications of the CHART studies. 2008;4(1):103.
17.
17. PalazzuoliA,RuoccoG,PellegriniM,etal. Prognostic significance of hyperuricemia in patients with acute heart failure. 2016;117(10):1616-1621.
DOI: doi.org/10.1093/eurheartj/ehl193
18.
18. Pascual‐Figal DA, Hurtado‐Martínez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes MJEjohf. Hyperuricaemia and long‐term outcome after hospital discharge in acute heart failure patients. 2007;9(5):518-524.
19.
19. HuangW-M,HsuP-F,Cheng H-M, et al. Determinants and prognostic impact of hyperuricemia in hospitalization for acute heart failure. 2015:CJ-15-0964.
20.
20.HuangG,QinJ,DengX,etal. Prognostic value of serum uric acid in patients with acute heart failure: A meta-analysis. 2019;98(8).
21.
21. HuangH,HuangB,LiY,etal. Uric acid and risk of heart failure: a systematic review and meta‐analysis. 2014;16(1):15-24.
DOI: doi.org/10.1016/j.ejim.2008.04.007
No translate

Files

PDF
Article Views323
Document Views2
Downloads9
Section NGHIÊN CỨU LÂM SÀNG
Issue Số 94+95 , 2021
Category BỆNH SUY TIM
Pages 106-113
Copyright Holder 2021 Tạp chí Tim mạch học Việt Nam

Related articles section label

Related articles

Related articles category hint

More articles

Hiệu quả và tính an toàn của finerenone ở bệnh nhân suy tim phân suất tống máu bảo tồn (HFpEF): Tổng quan hệ thống và phân tích tổng hợp

Bối cảnh: Finerenone hiện nay đang được quan tâm trong điều trị suy tim phân suất tổng máu bảo tồn (HFpEF). Mục tiêu: Nghiên cứu với mục tiêu đánh giá hiệu quả của finerenone ở những bệnh nhân HFpEF. Phương pháp: Sử dụ...

Chi tiết bài báo
PDF
DOI: 10.58354/jvc.116.2025.891
216
Hà Tân